Pacific Biosciences of California (PACB) Stock Overview
Designs, develops, and manufactures sequencing solution to resolve genetically complex problems. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
PACB Community Fair Values
Create NarrativeSee what 46 others think this stock is worth. Follow their fair value or set your own to get alerts.
Pacific Biosciences of California, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.64 |
| 52 Week High | US$2.72 |
| 52 Week Low | US$0.85 |
| Beta | 2.1 |
| 1 Month Change | 29.13% |
| 3 Month Change | 1.23% |
| 1 Year Change | -10.87% |
| 3 Year Change | -78.19% |
| 5 Year Change | -88.24% |
| Change since IPO | -90.02% |
Recent News & Updates
Further Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Could Introduce Price Risks After 38% Bounce
Oct 14
Is Pacific Biosciences of California (NASDAQ:PACB) A Risky Investment?
Jul 29Recent updates
Further Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Could Introduce Price Risks After 38% Bounce
Oct 14Is Pacific Biosciences of California (NASDAQ:PACB) A Risky Investment?
Jul 29Pacific Biosciences: The Shift To Razor-Blade Economics Could Be A Game Changer
Jul 23Further Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Could Introduce Price Risks After 29% Bounce
Jul 11Potential Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Not Without Risk
May 16
Vega Shipments, SMRT Cells And Revio Chemistry Will Boost Efficiency
Advancements in technology and cost efficiencies are poised to drive revenue growth and improve margins as the platform scales and becomes more widely adopted.Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock
Feb 26Revenue Downgrade: Here's What Analysts Forecast For Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Feb 22Pacific Biosciences of California, Inc. (NASDAQ:PACB) Might Not Be As Mispriced As It Looks After Plunging 26%
Feb 08Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Intrinsic Value Is Potentially 93% Above Its Share Price
Dec 10Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
Nov 12Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company
Nov 07Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?
Oct 16Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely
Sep 20Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing
Aug 21Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper
Jul 02We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt
Jun 08Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas
Jun 03These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat
Apr 25It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks
Apr 16Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership
Mar 19Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth
Feb 08With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For
Feb 01What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S
Dec 18Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?
Nov 13The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%
Aug 28Shareholder Returns
| PACB | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.2% | 1.9% | 0.1% |
| 1Y | -10.9% | -12.6% | 14.7% |
Return vs Industry: PACB exceeded the US Life Sciences industry which returned -12.6% over the past year.
Return vs Market: PACB underperformed the US Market which returned 14.7% over the past year.
Price Volatility
| PACB volatility | |
|---|---|
| PACB Average Weekly Movement | 11.5% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PACB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PACB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 575 | Christian O. Henry | www.pacb.com |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.
Pacific Biosciences of California, Inc. Fundamentals Summary
| PACB fundamental statistics | |
|---|---|
| Market cap | US$492.61m |
| Earnings (TTM) | -US$526.36m |
| Revenue (TTM) | US$156.11m |
Is PACB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PACB income statement (TTM) | |
|---|---|
| Revenue | US$156.11m |
| Cost of Revenue | US$113.09m |
| Gross Profit | US$43.02m |
| Other Expenses | US$569.38m |
| Earnings | -US$526.36m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.75 |
| Gross Margin | 27.56% |
| Net Profit Margin | -337.17% |
| Debt/Equity Ratio | 1,056.2% |
How did PACB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/20 16:41 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pacific Biosciences of California, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Kyle Mikson | Canaccord Genuity |
| David Westenberg | CL King & Associates, Inc. |